SBSteven Michael Blum

Steven Michael Blum

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Steven Michael Blum has a total of 214 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplementary Figures S1-S5 from Spatial Organization of Tumor-Infiltrating B Cells Informs Immune Checkpoint Inhibitor Response in Claudin 18.2–Expressing Gastric Cancer

    by Joseph J. Zhao, Choong-Kun Lee, Allison S.Y. Chan, Steven Blum, Chang Li, Haoran Ma, Wenyi Luo, Supriya Srivastava, Huey Yew Jeffrey Lum, Sheng Cong Norbert Tay, et al.

    Figure S1: Quality-control parameters and sensitivity analyses of CLDN18.2 microenvironmental and pathway changes Figure S2: Additional sensitivity survival analyses of the YCC cohort and CheckMate 649 trial Figure S3: Features of cellular neighbourhoods and correlation with progression-free survival Figure S4: Supplementary analyses to digital spatial profiling Figure S5: B/plasma cell enrichment scores across the tumor-stroma interface

  • Open Access

    Supplementary Tables 1-4 from Spatial Organization of Tumor-Infiltrating B Cells Informs Immune Checkpoint Inhibitor Response in Claudin 18.2–Expressing Gastric Cancer

    by Joseph J. Zhao, Choong-Kun Lee, Allison S.Y. Chan, Steven Blum, Chang Li, Haoran Ma, Wenyi Luo, Supriya Srivastava, Huey Yew Jeffrey Lum, Sheng Cong Norbert Tay, et al.

    Supplementary Tables 1-4 from Spatial Organization of Tumor-Infiltrating B Cells Informs Immune Checkpoint Inhibitor Response in Claudin 18.2–Expressing Gastric Cancer

  • Open Access

    Immune Responses in Checkpoint Inhibitor–Associated Cardiovascular Immune–Related Adverse Events

    by Kerry L. Reynolds, Alexandra-Chloé Villani, Zsófia Dora Drobni, Tomas G. Neilan, Han Zhu, Noah S. Wagner, Justin M. Balko, Reilly Fankhauser, Javid J. Moslehi, Nicolas L. Palaskas, et al.

  • Multiomic analysis of malignant ascites defines RORC -expressing dendritic cells at sites of metastasis

    by Steven M. Blum, Thomas L. Chan, Neal P. Smith, Courtney Ambrose, Katherine H. Xu, Alice Tirard, Nandini Samanta, Sidney Martin, Roya Best, Elizabeth Tuttle, et al.

    Malignant ascites is caused by the peritoneal dissemination of cancer and has a poor prognosis. Here, we performed multiomic analyses on ascites samples from patients with cancer and identified RORC -expressing dendritic cells ( RORC DCs) enriched in malignant ascites. RORC DCs expressed PIGR and were transcriptionally similar to murine RORγt + DCs/Thetis cells implicated in immune tolerance. We devised a high-purity sorting strategy to enable in vitro experiments with patient-derived RORC DCs, which indicated that these cells were phenotypically stable and stimulated T cell proliferation while attenuating IFNG expression. Multiplexed immunofluorescence identified RORC DCs in primary tumors and demonstrated their enrichment in regional lymph node metastases. These results associate human RORC DCs with advanced malignancies and suggest a role for these cells in the tumor microenvironment.

  • Open Access

    Spatial Organization of Tumor-Infiltrating B Cells Informs Immune Checkpoint Inhibitor Response in Claudin 18.2–Expressing Gastric Cancer

    by Joseph J. Zhao, Choong-Kun Lee, Allison S.Y. Chan, Steven Blum, Chang Li, Haoran Ma, Wenyi Luo, Supriya Srivastava, Huey Yew Jeffrey Lum, Sheng Cong Norbert Tay, et al.

    Purpose: Claudin 18.2 (CLDN18.2), a tight junction protein normally expressed in the gastric epithelium and rendered accessible during malignant transformation, has emerged as a key therapeutic target. Here, we seek to characterize the immune microenvironment of CLDN18.2-expressing gastric cancer and identify immune features associated with CLDN18.2 expression status. Experimental Design: Tumor-immune features were profiled in 103 patients with HER2-neg/low advanced gastric cancer treated with first-line immune checkpoint inhibitor (ICI) using multiplex immunohistochemistry [7,423,483 cells across 2,315 regions of interest (ROI)]. The findings were validated in five published whole-transcriptome sequencing/microarray cohorts (1,521 samples), including the landmark CheckMate 649 phase III trial. Spatial immune architecture was assessed by cellular neighborhood analysis. Digital spatial profiling (DSP) was performed on 480 ROIs from a CLDN18.2-annotated tissue microarray (75 patients). Results: CLDN18.2high tumors showed reproducible enrichment of humoral pathways, with higher CD20+ B-cell density and enrichment of B-cell/plasma-cell signatures. CLDN18.2 status alone was not associated with response or survival on first-line ICI therapy; in CLDN18.2low tumors, B-cell enrichment was associated with ICI benefit, unlike CLDN18.2high tumors. Spatial analyses indicated that CLDN18.2high tumors preferentially harbored tumor-infiltrating B cells, rather than tertiary lymphoid structure/lymphoid aggregate–like neighborhoods, and this tumor-compartment localization was associated with diminished ICI benefit. DSP confirmed that CD20+ B-cell enrichment was most pronounced within tumor regions, alongside compartment-specific activation of humoral and extrafollicular response programs and interferon-associated and remodeling signatures. Conclusions: CLDN18.2high gastric cancer exhibits a humoral-enriched microenvironment with increased tumor-infiltrating B cells and spatial immune organization associated with reduced ICI benefit. Spatial and humoral-state biomarkers may inform ongoing CLDN18.2-directed combination trials.

  • Open Access

    IL-6 in Checkpoint Myocarditis

    by Daniel A. Zlotoff, Karishma Rahman, Steven M. Blum


  • Open Access

    Tumor location as a risk factor for severe immune-related adverse events

    by Steven M Blum, Ben Ouyang, Leyre Zubiri, Daniel Leonard, Kamil Slowikowski, Mike Wang, Kelley A Grealish, Nora K Hathaway, Gabriel Molina, Nishi Shah, et al.

    Immune-related adverse events (irAEs) can cause severe morbidity and mortality, and they impair treatment with immune checkpoint inhibitors (ICI). Risk factors for irAEs are not well understood. We observed cases of patients having tumor deposits in their liver and lung during a workup of irAEs, which led us to hypothesize that the presence of tumor in an organ would increase the odds of developing severe irAEs in that organ. We then performed a retrospective cohort study that included patients who received an ICI for the treatment of cancer and were hospitalized between February 2011 and November 2021 at the Massachusetts General Hospital. We reviewed 384 patients hospitalized with concern for any irAE. A clinical diagnosis of ICI-related hepatitis occurred in 18% of patients with liver tumor deposits versus 8% of those without (OR 2.23, 95% CI (1.10 to 4.43), p=0.02). ICI-related pneumonitis occurred in 10% of patients with lung tumor deposits versus 4.4% of those without (OR 2.45, 95% CI (1.06 to 6.36), p=0.047). A combined analysis for liver and lung lesions demonstrated that the presence of tumor deposits in an organ increased the odds of having an irAE in that organ by over twofold (OR 2.31, 95% CI (1.34 to 3.99), p=0.002). Our results suggest that the presence of tumor deposits may represent a novel risk factor for severe irAEs in that organ.


  • Enhancing Precision in Detecting Severe Immune-Related Adverse Events: Comparative Analysis of Large Language Models and International Classification of Disease Codes in Patient Records

    by Virginia H. Sun, Julius C. Heemelaar, Ibrahim Hadzic, Vineet K. Raghu, Chia-Yun Wu, Leyre Zubiri, Azin Ghamari, Nicole R. LeBoeuf, Osama Abu-Shawer, Kenneth L. Kehl, et al.

    PURPOSE: Current approaches to accurately identify immune-related adverse events (irAEs) in large retrospective studies are limited. Large language models (LLMs) offer a potential solution to this challenge, given their high performance in natural language comprehension tasks. Therefore, we investigated the use of an LLM to identify irAEs among hospitalized patients, comparing its performance with manual adjudication and International Classification of Disease (ICD) codes. METHODS: Hospital admissions of patients receiving immune checkpoint inhibitor (ICI) therapy at a single institution from February 5, 2011, to September 5, 2023, were individually reviewed and adjudicated for the presence of irAEs. ICD codes and an LLM with retrieval-augmented generation were applied to detect frequent irAEs (ICI-induced colitis, hepatitis, and pneumonitis) and the most fatal irAE (ICI-myocarditis) from electronic health records. The performance between ICD codes and LLM was compared via sensitivity and specificity with an α = .05, relative to the gold standard of manual adjudication. External validation was performed using a data set of hospital admissions from June 1, 2018, to May 31, 2019, from a second institution. RESULTS: Of the 7,555 admissions for patients on ICI therapy in the initial cohort, 2.0% were adjudicated to be due to ICI-colitis, 1.1% ICI-hepatitis, 0.7% ICI-pneumonitis, and 0.8% ICI-myocarditis. The LLM demonstrated higher sensitivity than ICD codes (94.7% v 68.7%), achieving significance for ICI-hepatitis ( P < .001), myocarditis ( P < .001), and pneumonitis ( P = .003) while yielding similar specificities (93.7% v 92.4%). The LLM spent an average of 9.53 seconds/chart in comparison with an estimated 15 minutes for adjudication. In the validation cohort (N = 1,270), the mean LLM sensitivity and specificity were 98.1% and 95.7%, respectively. CONCLUSION: LLMs are a useful tool for the detection of irAEs, outperforming ICD codes in sensitivity and adjudication in efficiency.


  • Open Access

    Patient-derived exosomes facilitate therapeutic targeting of oncogenic MET in advanced gastric cancer

    by Sujin Hyung, Jihoon Ko, You Jeong Heo, Steven M. Blum, Seung Tae Kim, Se Hoon Park, Joon Oh Park, Won Ki Kang, Ho Yeong Lim, Samuel J. Klempner, et al.

    Gastric cancer (GC) with peritoneal metastases and malignant ascites continues to have poor prognosis. Exosomes mediate intercellular communication during cancer progression and promote therapeutic resistance. Here, we report the significance of exosomes derived from malignant ascites (EXO Ascites ) in cancer progression and use modified exosomes as resources for cancer therapy. EXO Ascites from patients with GC stimulated invasiveness and angiogenesis in an ex vivo three-dimensional autologous tumor spheroid microfluidic system. EXO Ascites concentration increased invasiveness, and blockade of their secretion suppressed tumor progression. In MET -amplified GC, EXO Ascites contain abundant MET; their selective delivery to tumor cells enhanced angiogenesis and invasiveness. Exosomal MET depletion substantially reduced invasiveness; an additive therapeutic effect was induced when combined with MET and/or VEGFR2 inhibition in a patient-derived MET -amplified GC model. Allogeneic MET-harboring exosome delivery induced invasion and angiogenesis in a MET non-amplified GC model. MET -amplified patient tissues showed higher exosome concentration than their adjacent normal tissues. Manipulating exosome content and production may be a promising complementary strategy against GC.


  • Effects of immune‐related adverse events (irAEs) and their treatment on antitumor immune responses

    by Steven M. Blum, Sherin J. Rouhani, Ryan J. Sullivan

    Summary: Immune checkpoint inhibitors (ICIs) are potentially life‐saving cancer therapies that can trigger immune‐related adverse events (irAEs). irAEs can impact any organ and range in their presentation from mild side effects to life‐threatening complications. The relationship between irAEs and antitumor immune responses is nuanced and may depend on the irAE organ, the tumor histology, and the patient. While some irAEs likely represent an immune response against antigens shared between tumor cells and healthy tissues, other irAEs may be entirely unrelated to antitumor immune responses. Clinical observations suggest that low‐grade irAEs have a positive association with responses to ICIs, but the correlation between severe irAEs and clinical benefit is less clear. Currently, severe irAEs are typically treated by interrupting or permanently discontinuing ICI treatment and administering empirically selected systemic immunosuppressive agents. However, these interventions could potentially diminish the antitumor effects of ICIs. Efforts to understand the mechanistic relationship between irAEs and the tumor microenvironment have yielded meaningful insights and nominated therapeutic targets for irAE management that may preserve or even boost ICI efficacy. We explore the clinical and molecular relationship between irAEs and antitumor immunity as well as the role that irAE treatments may play in shaping antitumor immune responses.